This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

An immunotherapy-based regimen combining durvalumab and the PARP inhibitor olaparib demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results presented by researchers from The University of Texas MD Anderson Cancer Center.

In the global phase 3 DUO-E trial, treatment with durvalumab plus chemotherapy followed by durvalumab and olaparib achieved a median overall survival of 51.1 months, which was 11.5 months longer than with chemotherapy alone.

The findings were presented today at the European Society for Medical Oncology Congress 2026 by principal investigator Shannon Westin, professor of gynecologic oncology and reproductive medicine.

"These results demonstrate that combining immunotherapy with a PARP inhibitor can deliver durable survival benefits for patients with advanced or recurrent endometrial cancer," Westin said. "The findings are particularly noteworthy for patients with pMMR tumors, who represent the majority of cases and have traditionally had fewer effective treatment options."

The trial randomized 718 patients with advanced or recurrent endometrial cancer to receive one of three treatment regimens. One group received chemotherapy alone followed by placebo in the maintenance phase. The other two groups received chemotherapy with durvalumab followed by durvalumab with or without olaparib in the maintenance phase.

The study previously met its primary progression-free survival end points. The current analysis evaluated overall survival and long-term safety profiles. No new safety concerns were observed, and side effects remained consistent with previous findings.

Source link